Therefore, a combined evaluation of ChREBP, GLUT1 and GLUT2 protein expression profile may provide a new diagnostic and prognostic marker for HCC, that might be useful in improving patient treatment and survival. The gene discussed is SLC2A1; the disease is hepatocellular carcinoma.